Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. [electronic resource]
Producer: 20180319Description: 249-251 p. digitalISSN:- 1537-4513
- Aged
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents -- adverse effects
- Autoantibodies -- blood
- Carcinoma, Non-Small-Cell Lung -- complications
- Diabetic Ketoacidosis -- diagnosis
- Drug-Related Side Effects and Adverse Reactions -- diagnosis
- Glutamate Decarboxylase -- immunology
- Humans
- Immunotherapy -- adverse effects
- Insulin -- therapeutic use
- Lung Neoplasms -- complications
- Male
- Programmed Cell Death 1 Receptor -- immunology
- Remission Induction
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.